EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liposomes in Cancer Therapy: How Did We Start and Where Are We Now

Melody D Fulton iD, Wided Najahi-Missaoui

International Journal of Molecular Sciences · 01.04.2023 · 24 (7) · 6615

DOI: 10.3390/ijms24076615 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.04.2023. Verfasst von Melody D Fulton und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Arts and Sciences, Washington State University, Pullman, WA 99164, USA. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 266-mal zitiert (Crossref) und nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since their first discovery in the 1960s by Alec Bangham, liposomes have been shown to be effective drug delivery systems for treating various cancers. Several liposome-based formulations received approval by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), with many others in clinical trials. Liposomes have several advantages, including improved pharmacokinetic properties of the encapsulated drug, reduced systemic toxicity, extended circulation time, and targeted disposition in tumor sites due to the enhanced permeability and retention (EPR) mechanism. However, it is worth noting that despite their efficacy in treating various cancers, liposomes still have some potential toxicity and lack specific targeting and disposition. This explains, in part, why their translation into the clinic has progressed only incrementally, which poses the need for more research to focus on addressing such translational limitations. This review summarizes the main properties of liposomes, their current status in cancer therapy, and their limitations and challenges to achieving maximal therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsHumansLiposomesDrug Delivery Systems

Stichwörter der Autor:innen

PEGylationanticancer therapycancerliposomesnanoparticletargeted drug delivery

Substanzen

LiposomesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Chemistry, College of Arts and Sciences, Washington State University, Pullman, WA 99164, USA.
  • Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA 30602, USA.

ORCID-Profile: Melody D Fulton

Zitieren

APA

Fulton, M. D., & Najahi-Missaoui, W. (2023). Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. International Journal of Molecular Sciences, 24(7), 6615. https://doi.org/10.3390/ijms24076615

Vancouver

Fulton MD, Najahi-Missaoui W. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. International Journal of Molecular Sciences. 2023;24(7):6615. doi:10.3390/ijms24076615

BibTeX
@article{Fulton2023,
  author = {Fulton, Melody D and Najahi-Missaoui, Wided},
  title = {Liposomes in Cancer Therapy: How Did We Start and Where Are We Now},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {7},
  pages = {6615},
  doi = {10.3390/ijms24076615}
}
Kostenlos starten →